Form 4: Cassava Sciences Executive Granted Stock Options
SEC Form 4 Filing
Freda Nassif, Chief Commercial Officer of Cassava Sciences, was granted 100,000 stock options on November 18, 2024.
Summary
- Freda Nassif, the Chief Commercial Officer of Cassava Sciences, was granted 100,000 stock options on November 18, 2024.
- The options have an exercise price of $27.95 per share.
- The options vest in four equal annual installments, with the first 25% vesting on November 18, 2025.
- The options expire on November 18, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the stock options is dependent on the future performance of Cassava Sciences' stock price.
- If the stock price does not increase above the exercise price, the options will have no value.
Future Outlook
The stock options will vest over the next four years, incentivizing the executive to contribute to the company's long-term success.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of four years is also typical for such grants.
- The exercise price is set at the market price at the time of the grant, which is standard practice.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 11/18/2024 | Date of the stock option grant. |
| 11/18/2025 | First vesting date of 25% of the stock options. |
| 11/18/2034 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, Cassava Sciences, SAVA, Freda Nassif, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.